Mexico’s COFEPRIS Reset: What Faster Approvals Mean for FIH Sponsors

PRACTICAL GUIDE | 2026

Mexico's COFEPRIS Reset: What Faster Approvals Mean for FIH Sponsors

Mexico is rewriting its regulatory timelines. Here is what actually changed, which clocks an FIH sponsor must track, and what to verify before filing.

By Julio G. Martinez-Clark

CEO, bioaccess®

Last verified: September 2026 | General information only—not legal or regulatory advice. Rules change frequently; confirm the strategy with qualified regulatory counsel.

Publishing package

COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) is Mexico’s federal health regulator. FIH means first-in-human — the first time an investigational product is given to people. CONBIOÉTICA (Comisión Nacional de Bioética) is Mexico’s National Bioethics Commission. For context: FDA is the United States Food and Drug Administration, EMA is the European Medicines Agency, MHRA is the United Kingdom’s Medicines and Healthcare products Regulatory Agency, TGA is Australia’s Therapeutic Goods Administration, and MDSAP is the Medical Device Single Audit Program.

What actually changed at COFEPRIS?

Five developments, all within the last eighteen months, are reshaping how Mexico handles clinical research and medical-device approvals:

• New commissioner. Víctor Hugo Borja took office as Federal Commissioner of COFEPRIS in January 2026 (publicly reported), bringing new leadership to the agency.
• A presidential-level mandate. The May 2025 Plan México announcement cut clinical-research protocol review from 115 days to 40 days, with a stated goal of reaching two weeks. In 2026, Health Minister David Kershenobich publicly stated a reduction in clinical-trial authorization timelines from roughly 120 days to about 30 days. Treat the 30-day figure as a reported target and political commitment, not an established average.
• Legal reform. A January 15, 2026 decree amended Mexico’s General Health Law (Ley General de Salud), driving clinical-research reform, with COFEPRIS–CONBIOÉTICA coordination on implementation.
• Regulatory reliance. A Regulatory Reliance agreement recognizes evaluations by FDA, EMA, MHRA, and Health Canada to expedite clinical-research protocols — Mexico now leans on work already done by major regulators instead of re-reviewing everything.
• Broad simplification. COFEPRIS procedures were cut from 340 to 125, requirements were halved, and resolution times were reduced from 100 days to 24 days across the agency.

There is also an abbreviated drug pathway, in force since September 1, 2025, that gives decisions in 45 business days for medicines already authorized by FDA or EMA. The trend is the same everywhere in the agency: fewer steps, shorter clocks, and recognition of trusted foreign evaluations.

What are the three clocks an FIH sponsor must track?

Sponsors routinely mix these up. Keep them separate:

Clock	What is reported	Status
Clinical-trial protocol review —	~120 days → ~30 days	Announced by the Health Minister in 2026; political commitment, not an established average. Verify on filing day.
Device registration, abbreviated pathway —	~30 business days	In force since September 1, 2025. For devices with prior authorization (within the past 5 years) by FDA, EMA, Health Canada, TGA, or MDSAP. Replaces the standard 3–5-month route. 2026 health-law updates extended registration validity to 10 years on this pathway.
Ethics committee / IRB review —	~4–6 weeks (benchmark)	A separate clock from the COFEPRIS protocol authorization. Runs on committee cadence, not on the agency’s timeline.

Does Mexico re-enter the fast-country conversation?

For years, Mexico sat in the slow lane of our planning: six to nine months from filing to first patient in. If the reported ~30-day protocol review holds in practice, and ethics runs its ~4–6 weeks in parallel rather than sequentially, Mexico moves meaningfully closer to the fast corridor we have long associated with Panama, Chile, El Salvador, and Costa Rica.

That is the opportunity in Mexico’s COFEPRIS Reset: What Faster Approvals Mean for FIH Sponsors — a major market with deep investigator infrastructure and large patient populations, now paired with review timelines that no longer disqualify it on speed. It is not the same as proven speed. Until sponsors and CROs have filed and measured real-world clocks across several submissions, Mexico belongs on the watchlist with an asterisk, not in the fast corridor by default.

What should FIH sponsors verify before filing in Mexico?

Run this checklist on filing day, not at the strategy stage:

1. Current COFEPRIS protocol-authorization timeline. Ask for the current published clock and recent measured performance — not the 2026 announcement.
2. Abbreviated-pathway eligibility for the exact product. Confirm the device holds prior authorization from a recognized authority within the past 5 years and that the product class qualifies.
3. Registration validity. Confirm the 10-year validity period under the 2026 health-law updates is in force for your product on the abbreviated pathway.
4. Ethics pathway and CONBIOÉTICA coordination. Map the committee route, meeting cadence, and any national bioethics requirements before modeling the startup clock.
5. Parallel submission strategy. Confirm that ethics committee and regulator submissions can run in parallel for your study type — the biggest timeline accelerator available.
6. Import mechanics. Fold the investigational-product import permit into the startup clock; a fast protocol authorization means nothing if product is stuck at the border.
7. Local representation. Mexico requires local registration-holder mechanics for device registration — arrange the holder before filing, not after.

Frequently asked questions

Did COFEPRIS really cut clinical-trial approvals from 120 days to 30?

Health Minister David Kershenobich publicly stated a 120-to-30-day reduction in clinical-trial authorization timelines in 2026. Treat it as a reported target and political commitment, not an established average. Verify the current clock on filing day.

What is the abbreviated device pathway?

In force since September 1, 2025: decisions in about 30 business days for medical devices already authorized (within the past 5 years) by FDA, EMA, Health Canada, TGA, or MDSAP. It replaces the standard 3–5-month route, and 2026 health-law updates extended registration validity to 10 years on this pathway.

How long does ethics review take in Mexico?

The working benchmark is ~4–6 weeks — a separate clock from COFEPRIS protocol authorization, running on committee cadence.

Who runs COFEPRIS now?

Víctor Hugo Borja became Federal Commissioner of COFEPRIS in January 2026 (publicly reported).

Will FDA accept data from an FIH trial run in Mexico?

FDA accepts ICH-GCP-compliant data from qualified sites — it does not require a US or EU postal code. What matters is GCP compliance, a trained IRB, and qualified investigators and staff.

Is Mexico now as fast as Panama or Chile?

Not proven yet. If the announced timelines hold in practice, Mexico becomes competitive. Until measured clocks exist across several filings, model Mexico with an asterisk — and parallelize ethics and regulator submissions.

Mexico’s COFEPRIS Reset: What Faster Approvals Mean for FIH Sponsors, in one sentence: a major market with new leadership, reliance on trusted foreign evaluations, and dramatically shorter announced clocks — worth a serious look for FIH programs, with verification built into the plan.

References

• COFEPRIS official announcements and communiqués (2025–2026).
• mexicobusiness.news coverage of COFEPRIS leadership and timeline reforms.
• Plan México announcement, May 2025 (clinical-research protocol review 115 → 40 days).
• January 15, 2026 decree amending the Ley General de Salud (clinical-research reform; COFEPRIS–CONBIOÉTICA coordination).
• COFEPRIS Regulatory Reliance agreement (FDA, EMA, MHRA, Health Canada) for clinical-research protocols.
• Abbreviated pathway in force September 1, 2025 (~30 business days for devices with qualifying prior authorizations).